Drug intelligence / Profile preview

ibotenic acid

Development stage
Unknown
Modality
Small Molecules
Administration
Intracerebral, Experimental Parenteral (laboratory Only)
01

Overview

Ibotenic acid is a naturally occurring alpha-amino acid and neurotoxin found in several Amanita mushroom species (including Amanita muscaria and Amanita pantherina). It is a conformationally-restricted analogue of glutamate and acts primarily as a potent, non-selective agonist at glutamate receptors, strongly activating NMDA, group I and II metabotropic glutamate receptors, and weakly activating AMPA and kainate receptors. Through in vivo decarboxylation, ibotenic acid also serves as a prodrug for muscimol, a potent GABAA and GABAA-ρ receptor agonist. Ibotenic acid is neurotoxic and widely used in research to selectively cause excitotoxic brain lesions in animal models, particularly for studying CNS function, learning, and neurodegeneration. It induces neuronal damage by overactivating glutamate receptors, leading to calcium overload and oxidative stress.[1][4][9][7]

Other names
(S)-2-amino-2-(3-hydroxyisoxazol-5-yl)acetic acidα-Amino-(3-hydroxy-5-isoxazolyl)acetic acid2552-55-8IBOIBOTENIC ACIDibotenate
02

Targets

AMPAR (AMPA receptor)Kainate-type ionotropic glutamate receptorNMDAR (Glutamate receptor ionotropic, NMDA)GRM1 (Metabotropic glutamate receptor 1)GRM3 (mGluR3)GRM5 (Metabotropic glutamate receptor 5)

Beyond the preview

Go deeper on ibotenic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibotenic acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call